logo
  

ACADIA Pharmaceuticals Inc. (ACAD) Sank Sharply After NDA Filing Delay

ACADIA Pharmaceuticals Inc. (ACAD) announced after the bell Wednesday that Uli Hacksell Ph.D., has retired as its Chief Executive Officer and as a member of the Board of Directors, effective today.

The company also announced that it has delayed its plans to submit its NUPLAZID NDA until the second half of 2015. The company had previously planned to submit the NDA in the first quarter of 2015.

ACADIA Pharmaceuticals gapped open sharply lower Thursday, but traded in a range for the majority of the session. Shares finished with a loss of 9.94 at $34.82 on the highest volume of the year. The stock sank to nearly a 1-month low.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
RELATED NEWS
Follow RTT